drugset / Trial / NCT00252785
Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to confirm the efficacy (superiority) of Symbicort® Turbuhaler® 160/4.5 µg twice daily for 8 weeks in comparison to Pulmicort® Turbuhaler® 200 µg twice daily + Theolong® tablet 200 mg twice daily.
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 160 ug | Inhaled |
| Subject | Budesonide | Small molecule | 200 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 4.5 ug | Inhaled |
| Subject | Theophylline | Small molecule | 200 mg | Oral |